Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5892_Библиотеки_им_академика_М_И_Перельмана
.pdf
398
https://t.me/med1917
Chemistry and Pharmacology of Drug Discovery
References
1. Patel, S. P.; Vasavda, C.; Ho, B.; Meixiong, J.; Dong, X.; Kwatra, S. G.
Cholestatic pruritus: emerging mechanisms and therapeutics. J. Am.
Acad. Dermatol. 2019, 81 (6), 1371–1378.
2. Kronsten, V.; Fitzpatrick, E.; Baker, A. Management of cholestatic
pruritus in paediatric patients with alagille syndrome: The King’s
College Hospital experience. J. Pediatr. Gastroenterol. Nutr. 2013, 57
(2), 149–154.
3. Tandon, P.; Rowe, B. H.; Vandermeer, B.; Bain, V. G. The efficacy
and safety of bile acid binding agents, opioid antagonists, or rifampin in
the treatment of cholestasis-associated pruritus. Am. J. Gastroenterol.
2007, 102 (7), 1528–1536.
4. Bachs, L.; Parés, A.; Elena, M.; Piera, C.; Rodés, J. Effects of long-
term rifampicin administration in primary biliary cirrhosis.
Gastroenterology 1992, 102 (6), 2077–2080.
5. McRae, C. A.; Prince, M.; Hudson, M.; Day, C. P.; James, O.; Jones,
D. Pain as a complication of use of opiate antagonists for symptom
control in cholestasis. Gastroenterology 2003, 125 (2), 591–596.
6. Mosi ska, P.; Fichna, J.; Storr, M. Inhibition of ileal bile acid
transporter: an emerging therapeutic strategy for chronic idiopathic
constipation. World J. Gastroenterol. 2015, 21 (24), 7436–7442.
7. Acosta, A.; Camilleri, M. Elobixibat and its potential role in chronic
idiopathic constipation. Therap. Adv. Gastroenterol. 2014, 7 (4), 167–
175.
8. Hegade, V. S.; Kendrick, S. F.; Jones, D. E. Drug treatment of pruritus
in liver diseases. Clin. Med. 2015, 15 (4), 351–357.
9. Al-Dury, S.; Marschall, H.-U. Ileal bile acid transporter inhibition for
the treatment of chronic constipation, cholestatic pruritus, and NASH.
Front. Pharmacol. 2018, 9,
10. Yuan, S.; Wang, D.-S.; Liu, H.; Zhang, S.-N.; Yang, W.-G.; Lv, M.;
Zhou, Y.-X.; Zhang, S.-Y.; Song, J.; Liu, H.-M. New drug approvals
for 2021: synthesis and clinical applications. Eur. J. Med. Chem. 2023,
245, 114898.
387830.
399
https://t.me/med1917
11. Efficacy and Safety Trial of Elobixibat in Patients with Chronic
12. 26 Week Efficacy and Safety Trial for Patients with Chronic Idiopathic
13. Gilberg, P.; Graffner, H.; Starke, I. IBAT Inhibitors for the Treatment
14. US FDA approves Bylvay for patients living with cholestatic pruritus
15. Harris, M. J.; Le Couteur, D. G.; Arias, I. M. Progressive familial
16. Turnpenny, P. D.; Ellard, S. Alagille syndrome: pathogenesis,
17. Samant, H.; Manatsathit, W.; Dies, D.; Shokouh-Amiri, H.; Zibari, G.;
18. Hofmann, A. F. The continuing importance of bile acids in liver and
19. Chothe, P. P.; Czuba, L. C.; Moore, R. H.; Swaan, P. W. Human bile
20. Davit-Spraul, A.; Gonzales, E.; Baussan, C.; Jacquemin, E. Progressive
21. Prussak, E. Medical and dental management of alagille syndrome: a
22. Vinayagamoorthy, V.; Srivastava, A.; Sarma, M. S. Newer variants of
23. Lemaigre, F. P. Notch signaling in bile duct development: new insights
24. Alrefai, W. A.; Gill, R. K. Bile acid transporters: structure, function,
Chapter 17. Odevixibat (Bylvay)
Idiopathic Constipation, Identifier NCT01833065, 2013.
Constipation, Identifier NCT01827592, 2015.
of Liver Disease, US Patent Appl. US 9,694,018 B1, Jul 4, 2017.
due to Alagille syndrome:
fda-approves-bylvay-for-patients-living-with-cholestatic-pruritus-dueto-alagille-syndrome/. Accessed Dec. 15, 2023.
intrahepatic cholestasis: genetic disorders of biliary transporters. J.
Gastroenterol. Hepatol. 2005, 20 (6), 807–817.
diagnosis and management. Eur. J. Hum. Genet. 2011, 20 (3), 251–257.
Boktor, M.; Alexander, J. S. Cholestatic liver diseases: an era of
emerging therapies. World J. Clin. Cases. 2019, 7 (13), 1571–1581.
intestinal disease. Arch. Intern. Med. 1999, 159 (22), 2647–2658.
acid transporter ASBT (SLC10A2) forms functional non-covalent
homodimers and higher order oligomers. Biochim. Biophys. Acta 2018,
1860 (3), 645–653.
familial intrahepatic cholestasis. Orphanet J. Rare Dis. 2009, 4 (1), 1.
review. Med. Sci. Monit. 2014, 20, 476–480.
progressive familial intrahepatic cholestasis. World J. Hepatol. 2021,
13 (12), 2024–2038.
raise new questions. Hepatology 2008, 48 (2), 358–360.
regulation and pathophysiological implications. Pharm. Res. 2007, 24
(10), 1803–1823.
https://www.ipsen.com/press-releases/u-s-
400
https://t.me/med1917
25. Hu, N.-J.; Iwata, S.; Cameron, A. D.; Drew, D. Crystal structure of a
26. Li, M.; Wang, Q.; Li, Y.; Cao, S.; Zhang, Y.; Wang, Z.; Liu, G.; Li, J.;
27. Zhang, E. Y.; Phelps, M. A.; Banerjee, A.; Khantwal, C. M.; Chang,
28. Bertolini, A.; Fiorotto, R.; Strazzabosco, M. Bile acids and their
29. Lewis, M. C.; Brieaddy, L. E.; Root, C. Effects of 2164U90 on ileal
30. Root, C.; Smith, C. D.; Winegar, D. A.; Brieaddy, L. E.; Lewis, M. C.
31. Tremont, S. J.; Lee, L. F.; Huang, H.-C.; Keller, B. T.; Banerjee, S. C.;
32. Huang, H.-C.; Tremont, S. J.; Lee, L. F.; Keller, B. T.; Carpenter, A. J.;
33. Starke, I.; Dahlstrom, M.; Blomberg, D. 1,5 Benzothiazepines and their
34. Starke, I.; Dahlstrom M.; Alenfalk, S.; Skjaret, T.; Lemurell, M.
Chemistry and Pharmacology of Drug Discovery
bacterial homologue of the bile acid sodium symporter ASBT. Nature
2011, 478 (7369), 408–411.
Gu, B. Apical sodium-dependent bile acid transporter, drug target for
bile acid related diseases and delivery target for prodrugs: current and
future challenges. Pharmacol. Ther. 2020, 212, 107539.
C.; Helsper, F.; Swaan, P. W. Topology scanning and putative threedimensional structure of the extracellular binding domains of the apical
sodium-dependent bile acid transporter (SLC10A2). Biochemistry
2004, 43 (36), 11380–11392.
receptors: modulators and therapeutic targets in liver inflammation.
Semin. Immunopathol. 2022, 44 (4),
bile acid absorption and serum cholesterol in rats and mice. J. Lipid
Res. 1995, 36 (5), 1098–1105.
Inhibition of ileal sodium-dependent bile acid transport by 2164U90. J.
Lipid Res. 1995, 36 (5), 1106–1115.
Both, S. R.; Carpenter, A. J.; Wang, C.-C.; Garland, D. J.; Huang, W.;
et al. Discovery of potent, nonsystemic apical sodium-codependent bile
acid transporter inhibitors (Part 1). J. Med. Chem. 2005, 48 (18), 5837–
5852.
Wang, C.-C.; Banerjee, S. C.; Both, S. R.; Fletcher, T.; Garland, D. J.;
et al. Discovery of potent, nonsystemic apical sodium-codependent bile
acid transporter inhibitors (Part 2). J. Med. Chem. 2005, 48 (18), 5853–
5868.
use as antihyperlipidemics, Int. Patent Appl. WO 02/50051 A1, Jun 27,
2002.
Peptides derivatives comprising thiazepine group for the treatment of
hyperlipidemic conditions, Int. Patent Appl. WO 03/106482 A1, Dec
24, 2003.
547–564.
401
https://t.me/med1917
35. Abrahamsson, H. R.; Gillberg, P. G. Use of an IBAT Inhibitor for the
36. Deeks, E. D. Odevixibat: first approval. Drugs 2021, 81 (15), 1781–
37. FDA Approval: Bylvay (odevixibat) capsules, for oral use:
38. Baumann, U.; Sturm, E.; Lacaille, F.; Gonzalès, E.; Arnell, H.;
39. Thompson, R.; Arnell, H., Artan, R.; Baumann, U.; Calvo, P. L.;
40. Efficacy and Safety of odevixibat in Patients with Alagille Syndrome
41. Handlon, A.; Hodgson, G.; Hyman, C. Hypolipidemic bicyclic
42. Starke, I.; Dahlstrom M.; Blomberg, D.; Alenfalk, S.; Skjaret, T.;
Chapter 17. Odevixibat (Bylvay)
Treatment of Constipation, US Patent Appl. US 7,514,421 B2, Apr 7,
2009.
1786.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215498s00
0lbl.pdf
Fischler, B.; Jørgensen, M. H.; Thompson, R. J.; Mattsson, J. P.;
Ekelund, M.; Lindström, E. Effects of odevixibat on pruritus and bile
acids in children with cholestatic liver disease: phase 2 study. Clin. Res.
Hepatol. Gastroenterol. 2021, 45 (5), 101751.
Czubkowski, P.; Dalgic, B.; D'Antiga, L.; Durmaz, Ö.; Fischler, B.;
Gonzalès, E. Odevixibat treatment in progressive familial intrahepatic
cholestasis: a randomized, placebo-controlled, phase 3 study. Lancet
Gastroenterol. Hepatol. 2022, 7, 830–42.
(ASSERT), Identifier NCT04674761, 2023.
derivatives, Int. Patent Appl. WO 98/38182, Sep. 3, 1998.
Lemurell, M. Benzothiazepine and benzothiadiazepine derivatives with
ileal bile acid transport (IBAT) inhibitory activity for the treatment
hyperlipidaemia, Int. Patent Appl. WO 03/022286 A1, Mar. 20, 2003.
Accessed Dec. 15, 2023.
https://t.me/med1917
Index
https://t.me/med1917
(S)-sulfinamide, 92
(S)-tert-leucine, 16
(S)-valine, 16
(S)-val-sulfonamide, 15
[5 + 1] cycloaddition, 193
“Black Box” warning, 327
“Black-Box” label, 127
“Magic Methyl” effect, 200,205
“Me-Too” drug, 383
“Z” sedative hypnotics, 300
+ssRNA, 5
1,1′-thiocarbonyl diimidazole, 193
1,2,4-oxadiazoles, 308
1,2,4-triazole, 122,127
1,3-dibromo-5,5-dimethylhydantoin, 91
1,3-β-D glucans synthase, 124
1,3-β-D glucans, 124
11β-hydroxysteroid dehydrogenase, 227
2,6-diisopropylphenol, 252
2-hydroxypyridine N-oxide, 24
3,5-dimethoxybenzene ring, 155
3-chymotrypsin-like protease inhibitor,
3-16
3CL protease, 3-16
pro
3-CL
inhibitor, 3-16
3TC, 30
3β-hydroxysteroid dehydrogenase, 227
4-hydroxybenzoic acid, 374
5-HT
, 364
1A
5-HT1B receptor, 277
5-HT
5-HT
5-HT
agonists, 277
1B/1D
receptor, 277
1D
receptor, 277
1F
5-HT2A, 364
6,6-dimethyl-3azabicyclo[3.1.0]hexane, 17
abrocitinib, 169
absolute lymphocyte count, 226
ACE, 6,7
acetanilide para-sulfonamide, 39
acetate salt, 372
acetylation, methylation, 201
acquired resistance, 150,188
acrylamide covalent warhead, 156
ACT-128800, 219
ACTH, 366,367
activation loop, 332
active catalytic site, 8
active kinase catalytic domain, 326
active pharmaceutical ingredients, 46
active plasma metabolites, 226
AD, 169
adalimumab, 219
ADCs, 188
additive effects, 312
Addyi, 364
adhesion inhibitors, 99
adrenocorticotropic hormone, 367
ADRs, 252
adult erythropoietic protoporphyria, 370
adverse drug reactions, 252
adverse events, 288
Agouti signaling protein
AgRP, 367
AIDS, 97-109
ainuovirine, 37
AIs, 99
AKT inhibitor, 154
Alagille syndrome, 381
albumin,158
ALC, 226,227
alcohol dehydrogenase, 227
aldehyde dehydrogenase, 227
aldo-keto reductase, 227
ALGS, 381-394
ALLINIs, 63-65
allosteric GABA-A subunit alpha-1
receptor modulators, 300
allosteric HIV-1 integrase inhibitors,
63-65
allosteric NNIBP, 38
allosteric site, 34
allylamines, echinocandins, 122
ALT, 288,393
altered metabolism, 199
amidomethyl ketones, 13
aminoindazole, 39
aminosalicylates,
Chemistry and Pharmacology of Drug Discovery, First Edition. Edited by Jie Jack Li.
© 2025 John Wiley & Sons, Inc. Published 2025 by John Wiley & Sons, Inc.
404
https://t.me/med1917
Chemistry and Pharmacology of Drug Discovery
amiselimod phosphate, 228
amiselimod, 220
amphotericin B, 123,128
anaphylactic reactions, 252
anemia, 178
anesthesia, 251-264
γ-aminobutyric acid receptor, 251-264
angiogenesis, 170
angiotensin converting enzyme, 6,7
anifrolumab, 329
annualized relapse rate, 233
antagonist of orexin receptors, 299-321
anti-apoptotic signaling, 153
antibiotic resistance, 122
antibody–drug conjugates, 188
antifungal CYP51, 129
antigen-presenting cells, 224
antileukemic activity, 168
antimycobacterial, 383
antiretroviral therapy, 31
API, 46,161
apoptosis, 178,199
appetite control, 366
apremilast, 342
area-under-the-curve, 18
Arlansa, 6,7
aromatic nucleophilic substitution, 192
aromatic residue-rich hERG channel,
335
ARR, 233
aryloxyl-pyridone, 47
ASBT, 386
ASIP, 367
aspartimide formation, 374,375
aspergillosis, 128
Asperigillus, 125,127
AST, 288,393
asthma, 170
atazanavir, 109
atogepant, 275,279,280
atopic dermatitis, 169
ATP binding pocket, 173,327
ATP-competitive inhibitors, 153
ATP-pockets, 327
atrioventricular block, 233
attachment Inhibitor, 97-119
AUC,18,106,135,190,287,334,370341,
342,393
autoimmune chronic inflammatory
diseases, 325
autoimmune disease, 169,217,329
autophagy, 201
auto-reactive lymphocytes, 225
AZD4547, 150
azidothymidine, 30
azoles, 122,125
AZT, 30
bacterial homologs, 387
BAF312, 219
barbiturates, 251
baricitinib, 169
Bartoli-type reaction, 110
basolateral amygdala, 368
BAT, 171,178
BBB, 226
BCRP efflux transporters, 287
BCRP, 109,287
beagle dogs, 68
bench top synthesis, 138
benzimidazole, 305,308,314
benzothiazepine,
251,300,383,384,388,394,395
benzothiazol-2-yl ketone, 11-16
benzothiophene, 281
best available therapy, 171
beyond the rule-of-5, 77
BGJ-398, 150,151
BI 224436, 64-65
bictegravir, 61
bile acid-conjugates, 384
bile acids, 384,385
bile salt export pump protein, 393
biliary cholangiocytes, 386
biliary excretion, 171
binding affinity
binimetinib, 159
BINOL, 138
biocatalysis, 291
bioisostere, 16,31,58,59
bis(pinacolato)diboron, 93
BIS, 255
bis-deoxychlorination, 348
405
https://t.me/med1917
Index
Bispectral Index, 255
blastomycosis, 128
blood creatine phosphokinase increase,
343
blood-brain barrier, 127,187188,226,261,306
BLU554, 151-152
BMS-626529, 105,107
BMS-663068, 105,107
BMS-986180, 65
boceprevir, 6,7,11,24
Boekelheide reaction, 70
brain metastases, 187
breakthrough migraine attacks, 280
breast cancer resistance protein
substrates, 137
bremelanotide, 363-380
bridging water molecule, 332
broad spectrum antifungal treatment,
123
BSC II category, 107
BSEP, 109,393
Büchi reactor, 316
bupropion, 364
Burgess reagent, 20,21
buspirone, 364
butterfly conformation, 34
Bylvay, 381-401
Cabenuva, 31,78
cabotegravir, 31, 53-76, 78
Caco-2 Pc, 101
Caco-2/PAMPA, 283
calcitonin gene-related peptide, 275
calcitonin receptor-like receptor, 278
cAMP accumulation, 371
cancer-associated phenotypes, 199
Candida albicans CYP51, 122,130
capsid protein inhibitor, 77-95
capsid–capsid interactions, 82
carbonyl reductases, 227
carboxylesterase 2, 342
cardiotoxicity, 19
cardiovascular stability, 255
cART, 31,54
caspofungin, 124
catalytic dyad, 7,8
catalytic hydrogenation reduction,
195,196
catalytic triad, 8,36, 57
cataplexy, 301
cation–π interactions, 84
CCR5 co-receptor, 98
CCR5-dependent JRFL strain, 101
CD, 218
CDK2, 174
cDNA, 98
cell cycle progression, 201
cell fusion, 98
cell proliferation, 169
cell specialization, 221
cell-to-cell fusion, 100
cellular membranes, 131
central dogma, 32
central nervous system, 217
ceralifimod, 219
CES 2, 342
CGRP antagonizing treatments, 281
CGRP receptor antagonist, 275-297
Chemical, Manufacturing, and Control,
259
chemokine receptor CCR7, 225
chemokines of B and T cells, 221
chemokines, 219
chemotactic responses, 221
chiral center inversion,159
chiral chromatography, 137
chlormidazole, 125
cholestasis-inducing disorders, 382
cholestatic liver disease, 382
cholesterol, 131,384
cholestyramine, 383
cholic acid, 384
chromatin configurations, 200
Chromobacterium violaceum, 291
chronotropic cardiac effects, 225
CI, 288
Cipepofol, 251-274
ciprofol, 251-274
circulating exposure accounts, 342
cis-infection mode, 100
Claisen condensation reaction, 139
Claisen rearrangement, 366
406
https://t.me/med1917
Chemistry and Pharmacology of Drug Discovery
class B G-protein-coupled receptor, 278
clinically relevant accumulation, 311
cLogP, 172
clotrimazole, 125,126
CLR, 278
C
, 43,45,171,190,123,135,208,259,
max
261, 287,334,339,341,342,341,342,393
CMC, 259
CNS depressants, 312
CNS, 217
co-crystal structure, 332,334,335
cognitive processing speed, 234
collagen-induced arthritis, 329
combination antiretroviral therapies, 54
combination therapies, 163
commensal gut bacteria, 218
comorbidities, 218
computed tomography, 178
confidence interval, 288
conformational entropy, 10
conformational shift, 205
coplanarity, 104
coronavirus disease-2019, 3-19
Coronavirus RNA genome, 5
corticomedullary junction, 223
corticosteroids, 218
cotransporter glycoprotein, 386
coupling reagent, 372
covalent inhibitor, 187
covalent inhibitory mechanism, 156,162
COVID-19, 3-19
CPE, 19
CPS, 234
Cremophor EL, 125,252252
Crohn’s disease
cryo-electron microscopy structure, 231
cryptococcal meningitis, 127
Cryptococcus neoformans, 125
crystalline form, 107
CSF, 301
CT, 178
CTD, 57,80
C-terminal domain, 7,57, 80
CXCR4-dependent LAI strain, 101
cyclic ketones, 13
cyclocondensation reaction, 348
cyclophilin A, 80
cynomolgus monkeys, 68
CYP 1A1, 227
CYP 2C9, 287
CYP1A2, 18
CYP2B6, 18
CYP2B6, 342
CYP2C19, 18
CYP2C8, 191
CYP2C9, 18,158
CYP2D6, 158
CYP2D6, 342
CYP3A, 208
CYP3A, 43, 86,158
CYP3A4 inactivator, 18
CYP3A4 inducer, 312
CYP3A4, 109,129,132,171,175,176,
191,227,283,285,306
CYP3A4/5 inhibitor, 17
CYP51 Inhibitor, 121-145
CYP51, 122
CypA, 80,81
cysteine protease, 8
cytochrome P450 monooxygenase, 130
cytokine receptors, 329
cytokine-driven inflammatory
conditions,327
cytokines, 219
cytopathic effect, 19
cytoplasm, 55,80
cytoplasmic catalytic tyrosine kinase
domain, 190
cytoplasmic transport, 80
cytotoxicity concentration, 85
D-amino acid, 281,283
dapaconazole, 125
daridorexant metabolites, 311
daridorexant, 299-321
DBDMH, 91
DdDp, 33
DDI, 18, 78,86,339
decarboxylation, 289
de-ethylation, 208
degradation, 222
delavirdine, 34
dematiaceous fungi, 128
407
https://t.me/med1917
Index
demyelination, 219
Dess–Martin periodinane, 90
deucravacitinib, 325-360
deuterated TYK2 inhibitor, 325-360
deuterium kinetic isotope effect, 325
deuteromethylamide, 325
DFG-motif, 153
diastereomeric ratio, 290
diastereoselectivity, 290
diaza-Wittig reaction, 344
diazepam, 251,300
dibromatin, 209
diketoacid, 31,58,60
diltiazem, 312
dimethylcyclopropylproline, 20,25
dipeptidyl peptidase-4 inhibitors, 6,7,14
Diprivan, 252
disassembly, of virion, 80
disease-modifying therapies, 218
dissolution rate, 105
disulfide formation, 394
DMF–DMA, 193,345
DMP, 90
DMPK, 157
DMTs, 218
DNA chain terminators, 31
DNA polymerase, 30-31,35
DNA repair, 201
DNA sequence, 200
DNA-dependent DNA polymerase, 33
DOAR, 303
doletegravir, 61,65
domain structure of JAKs, 171
dopamine, 364
DoR, 158-159
doravirine, 29-52
dose escalation studies, 208
dose-dependent manner, 178
dose-escalation phase, 209
dose-escalation protocol, 232
dose-limiting toxicities, 232
double-point mutants, 38
downstream functions in cells, 330
downstream signal transduction, 329
DPP-4 inhibitors, 6,7,14
dr, 290
drug metabolism and pharmacokinetics,
157
Drug-drug interaction, 339
drug–drug interactions, 18,78,109,
124,127,132,191,339
drug-resistant, 99
DS-8201, 188
dual JAK2/IRAK1 inhibitor, 167-185
dual orexin agonists, 303
duration of response, 158
DZNep, 200,201
EAE, 226
echinocandin, 124,125
econazole, 125,126
EDT, 372
Edurant, 32
efavirenz, 34,312
efflux ratio, 334
efflux, 308,334
EFV, 34
EGFR del19/T790M mutations, 154
EGFR, 154,187,189
EGFR-associated toxicities, 189
electrocardiograms, 233
elimination half-lives, 17,171,263
Ellman’s chiral auxiliary, 92
elobixibat, 383,384
elvitegravir, 58
enalapril, 6,7
enamide, 86
enantiomers, 62
endogenous substrates, 6
endosomal signaling, 280
endosomes, 279
enhancer of zeste homolog 2, 199
ensitrelvir, 4,5
enterocyte’s apical membrane, 387
enterohepatic circulation, 386
entry inhibitors, 98
envelop (E) protein, 5,6
envelope glycoprotein gp120, 98
enzymatic activity, 189
epigenetic regulation, 200
episodic migraine, 275-297
epithelioid sarcoma, 199-209
Epivir, 30
Соседние файлы в папке Библиотека им академика М.И. Перельмана